MORE ARTICLES YOU MAY LIKE

Dr Norio Mitsuhashi | Measuring Respiratory Motion to Improve Precision in Lung Radiation Therapy

Dr Norio Mitsuhashi | Measuring Respiratory Motion to Improve Precision in Lung Radiation Therapy

Dr Norio Mitsuhashi, former Professor of the Department of Radiation Oncology at Tokyo Women’s Medical University, leads revolutionary clinical research into optimising stereotactic body radiation therapy for lung cancer. Dr Mitsuhashi and his colleagues examine whether routinely available patient and tumour characteristics can predict respiratory tumour motion, a critical source of uncertainty in high precision radiotherapy. Their findings suggest that respiratory motion cannot be reliably inferred, and must instead be measured directly in every patient.

Professor Terry C. Hrubec | Clean is good – but is too clean better?

Professor Terry C. Hrubec | Clean is good – but is too clean better?

Quaternary ammonium compounds are a large class of compounds used as disinfectants in hospitals, restaurants, healthcare and animal care facilities, and are popular as household cleaners. With disease outbreaks increasing our fears about infections, the use of disinfectants has skyrocketed in recent years. Understandably, we all want to feel safe. However, as Professor Terry Hrubec from the Department of Biomedical Sciences of E. Via College of Osteopathic Medicine discovered, such products may be causing more harm than good.

Professor Abraham P. Lee | Delivering Cancer Immunotherapy with Acoustic-Electric Precision, AESOP’s Fact not Fable

Professor Abraham P. Lee | Delivering Cancer Immunotherapy with Acoustic-Electric Precision, AESOP’s Fact not Fable

Chimeric Antigen Receptor (CAR) T-cell therapy offers life-saving potential, particularly against blood cancers, but severe side effects such as cytokine release syndrome (CRS) limit its safety. These toxicities are linked to uncontrolled CAR expression levels on the T-cell surface. Led by Professor Abraham P. Lee, researchers at the University of California, Irvine, have developed an advanced microfluidic system, called the Acoustic-Electric Shear Orbiting Poration (AESOP) platform, to precisely control the dose of genetic material delivered into primary T cells. This innovation promises safer, more homogeneous, and highly effective cellular immunotherapies.